The evidence base consists primarily of animal studies with limited human clinical data
Additionally, Theta Nutrition was recently issued an official patent from the United States Patent Office, a rare distinction in the nutritional supplement industry
It is known that the CV protection effect of GLP-1RAs have been proven through eight large-scale clinical studies, including Evaluation of LIXisenatide in Acute coronary syndrome (ELIXA) [66], LEADER [44], Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN)-6 [67], Exenatide Study of Cardiovascular Event Lowering (EXSCEL) [68], Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes) [69], Researching Cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) [70], Peptide Innovation for Early Diabetes Treatment (PIONEER) 6 [67,71], and AMPLITUDE-O [51]
BioTrust GLP-1 Elevate Leads 2025 Appetite Control Trend With Natural Alternative to Ozempic As demand rises for needle-free GLP-1 support, BioTrust's plant-based formula uses clinically studied ingredients to help reduce cravings, promote satiety, and support metabolic wellness-without stimulants or prescriptions
IGF-1 Elevation as a Pharmacologic Signal CJC-1295's GHRH agonism produces dose-proportional GH elevation, which raises IGF-1
The bottom line: BPC-157 is one of the most talked-about recovery peptides, and the early science is interesting